Cystic fibrosis data spurs analysts to upgrade views on Vertex

Updated trial results from Vertex Pharmaceuticals’ experimental drug aimed at treating cystic fibrosis combined with its already approved drug, Kalydeco, spurred several stock analysts to increase expectations for the company’s shares...